Clinical Study Conducted by Florida Cancer Specialists & Research Institute Finds New Therapy May Improve Treatment Outcomes For Patients with Extensive-Stage Small Cell Lung Cancer

Fort Myers, Fla., November 9, 2022 – A study conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) evaluating the use of a new therapy to improve chemotherapy treatment outcomes was published in the October issue of the International Journal of Cancer Care and Delivery. FCS medical oncologist Lowell Hart, MD, FACP, is first author of the study, entitled “Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices.” Co-authors include Lucio Gordan, MD, FCS Chief Medical Officer of Therapeutics and Analytics, Ray Bailey, BPharm, RPh, FCS Senior Vice President of Pharmacy Services, Trevor Heritage, PhD, FCS Vice President of Informatics, and Kristen Boykin, PharmD, FCS Director of Pharmacy Operations.

Patients who receive chemotherapy treatment for extensive-stage small cell lung cancer (ES-SCLC), when cancer has spread beyond the lungs, frequently experience chemotherapy-induced myelosuppression (CIM), a condition that results in reduced production of white and red blood cells and/or platelets and can become severe. The FCS study evaluated CIM outcomes of patients treated with Trilaciclib, the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.

The study of adult patients receiving treatment at FCS clinic locations between Feb. 1 2021 and May 15 2022, concluded, “Early real world outcomes following treatment with Trilaciclib suggest a potential for reductions in CIM among patients with ES-SCLC.”

Dr. Gordan said, “Thanks to our ongoing participation in clinical research and real-world evidence (RWE) studies, FCS is on the leading edge of improving cancer treatments. We are able to offer our patients the most innovative therapies to achieve the best possible outcomes.”

“Protecting bone marrow function is especially important for patients with extensive-stage small cell lung cancer,” said Dr. Hart. “My colleagues and I are pleased with the promising results obtained during our statewide study.”

To read the full study abstract: https://journal.binayfoundation.org/article/38337-evaluation-of-chemotherapy-induced-myelosuppression-in-patients-with-extensive-stage-small-cell-lung-cancer-treated-with-trilaciclib-retrospective-an

# # #

For More Information, Contact:
Michelle Robey, Vice President of Marketing
Michelle.Robey@FLCancer.com
(813) 767-9398

Jen Bradley, Director of Corporate Communications
Jennifer.Bradley@FLCancer.com
(847) 280-1740